Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Imricor Medical SystemsASX:IMR 43 FCF Yield % is -4.60 as of Jul. 13, 2026. GuruFocus rates ASX:IMR with a GF Score™ of 43/100 and a GF Value™ of A$0.10 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 855 Medical Devices & Instruments companies, Imricor Medical Systems ranks worse than 64.56% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Imricor Medical Systems's FCF Yield % or its related term are showing as below:
ASX:IMR'
s FCF Yield % Range Over the Past 10 Years
Min: -168.36 Med: -13.37 Max: -4.38
Current: -4.6
During the past 8 years, the highest FCF Yield % of Imricor Medical Systems was -4.38%. The lowest was -168.36%. And the median was -13.37%.
ASX:IMR's FCF Yield % is ranked worse than 64.56% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: -0.42
vs ASX:IMR: -4.60
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Imricor Medical Systems FCF Yield % Related Terms
Imricor Medical Systems FCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Imricor Medical Systems's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Imricor Medical Systems FCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Imricor Medical Systems's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Imricor Medical Systems's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Imricor Medical Systems (ASX:IMR) has a FCF Yield % of -4.60 as of Jul. 13, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Imricor Medical Systems and its competitors. According to the industry distribution chart, Imricor Medical Systems ranks #552 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 64.6%.
Is Imricor Medical Systems' FCF Yield % too high?
Imricor Medical Systems' current FCF Yield % is -4.60. Based on the distribution chart, Imricor Medical Systems ranks #552 out of 855 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Imricor Medical Systems has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Imricor Medical Systems' FCF Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Imricor Medical Systems ranks #552 out of 855 companies for FCF Yield %. This places Imricor Medical Systems in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Devices & Instruments company?
A good FCF Yield % depends on the Medical Devices & Instruments industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Imricor Medical Systems and its competitors. Imricor Medical Systems's current FCF Yield % is -4.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imricor Medical Systems stock overvalued right now?
Based on GuruFocus' analysis, Imricor Medical Systems (ASX:IMR) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.10, compared to a current price of A$1.83 — trading 1725% above its estimated fair value. The current FCF Yield % is -4.60. Imricor Medical Systems' overall GF Score™ is 43/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Imricor Medical Systems (ASX:IMR), the current FCF Yield % is -4.60 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Imricor Medical Systems (ASX:IMR) Overvalued in 2026?
Based on GuruFocus' analysis, Imricor Medical Systems stock appears to be overvalued.
The current stock price of A$1.83 is trading 1725% above its estimated GF Value™ of A$0.10.
GuruFocus considers Imricor Medical Systems to be Significantly Overvalued.
Key valuation signals for ASX:IMR:
FCF Yield %: -4.60
GF Value™: A$0.10 vs. price of A$1.83 (1725% above fair value)
No single metric tells the full story. See the ASX:IMR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Imricor Medical Systems Inc is a medical device company that develops MRI-guided technology to address issues with traditional X-ray ablation procedures. Its principal business activities are designing, manufacturing, and selling MRI-compatible products for cardiac catheter ablation procedures to treat arrhythmias. The company's products include the Advantage-MR EP Recorder/Stimulator, Vision-MR Ablation Catheter, and Vision-MR Dispersive Electrode. Geographically, the company generates maximum revenue from Europe.
43GF Score
Get the complete analysis for ASX:IMR
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IMR has been successfully added to your 
